Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore

A phase II, randomized, double-blind trial

Li-Min Huang Department of Pediatrics; National Taiwan University Hospital; Taipei, TaiwanCorrespondence[email protected]

Bee-Wah Lee Mount Elizabeth Medical Centre; Singapore

Poh Chong Chan University Children’s Medical Institute; National University Hospital; Singapore

Michael Povey GlaxoSmithKline Vaccines; Wavre, Belgium

Ouzama Henry GlaxoSmithKline Vaccines; Philadelphia, PA USA

Figures & data

Figure 1. Study profile. MMRV_{new WS}: measles-mumps-rubella-varicella vaccine derived from newly established working seed virus stock. MMRV, combined measles-mumps-rubella-varicella vaccine derived from current working seed virus stock; ATP, according-to-protocol.

Table 1. Seroconversion rates and antibody GMTs in the MMRV_{new WS} and MMRV groups, 43 d after each dose (ATP cohort)

Download CSV Display Table

Table 2. Incidence of solicited local symptoms reported during the 4-d follow-up period in groups MMRV_{new WS} and MMRV (Total vaccinated cohort)

Download CSV Display Table

Table 3. Incidence of solicited general symptoms reported during the 43-d follow-up period in groups MMRV_{new WS} and MMRV (total vaccinated cohort)

Download CSV Display Table

Figure 2. Prevalence of fever (any intensity) during the 43-d follow-up period after the first dose (Total vaccinated cohort). MMRV_{new WS}: measles-mumps-rubella-varicella vaccine derived from newly established working seed virus stock. MMRV, combined measles-mumps-rubella-varicella vaccine derived from current working seed virus stock

Table 4. Composition of study vaccines

Download CSV Display Table

Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore

A phase II, randomized, double-blind trial

Table 1. Seroconversion rates and antibody GMTs in the MMRV_{new WS} and MMRV groups, 43 d after each dose (ATP cohort)

Table 2. Incidence of solicited local symptoms reported during the 4-d follow-up period in groups MMRV_{new WS} and MMRV (Total vaccinated cohort)

Table 3. Incidence of solicited general symptoms reported during the 43-d follow-up period in groups MMRV_{new WS} and MMRV (total vaccinated cohort)

Table 4. Composition of study vaccines

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore

A phase II, randomized, double-blind trial

Figures & data

Table 1. Seroconversion rates and antibody GMTs in the MMRVnew WS and MMRV groups, 43 d after each dose (ATP cohort)

Table 2. Incidence of solicited local symptoms reported during the 4-d follow-up period in groups MMRVnew WS and MMRV (Total vaccinated cohort)

Table 3. Incidence of solicited general symptoms reported during the 43-d follow-up period in groups MMRVnew WS and MMRV (total vaccinated cohort)

Table 4. Composition of study vaccines

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 1. Seroconversion rates and antibody GMTs in the MMRV_{new WS} and MMRV groups, 43 d after each dose (ATP cohort)

Table 2. Incidence of solicited local symptoms reported during the 4-d follow-up period in groups MMRV_{new WS} and MMRV (Total vaccinated cohort)

Table 3. Incidence of solicited general symptoms reported during the 43-d follow-up period in groups MMRV_{new WS} and MMRV (total vaccinated cohort)